Diaceutics’ Pharma Precision Medicine Readiness Report 2019: It’s time to rethink the testing—treatment relationship

The diagnostic testing ecosystem is broken, hindering the progress of Precision Medicine in 2019, according to Diaceutics’ just published Pharma Precision Medicine Readiness Report 2019. In this latest annual assessment of the state of Precision Medicine, Diaceutics calls on the Precision Medicine community to rethink the relationship between testing and treatment, and end the “siloed thinking that is denying patients access to the right tests and better treatments.”

In the Report, Diaceutics draws on its experience with more than 500 therapy/diagnostic projects and the insights derived from real-world data to depict the toll that this fragmented commercial approach is having on patients. The Report reveals the challenges and strategic mistakes that continue to impair the onward march of Precision Medicine, including those involving the diagnostic supply chain, relations between the Pharma and Lab industries, suboptimal investment in biomarker/therapy combinations, and core hurdles to optimal precision testing facing Pharma commercial teams.

Additionally, the Report

  • Describes Diaceutics’ solution to this broken diagnostic testing ecosystem through the global harmonization of clinical lab tests,
  • Identifies the megatrends characterizing Precision Medicine in 2019, and
  • Predicts the drivers and disruptors that will shape Precision Medicine in the next 3 to 5 years.

Download the full Diaceutics Pharma Precision Medicine Readiness Report 2019  here to get the full story on Precision Medicine!

Webinars & Podcasts

Podcast: How Diaceutics is repairing the diagnostic testing ecoystem for patients worldwide
Diaceutics CEO, Peter Keeling joins Pat Kenny on Newstalk FM to discuss how analyzing Big Data to implement better diagnostic testing can help patients access better treatment options for cancer and other life-threatening diseases....
Liquid Biopsy in NSCLC
View all

Expert Insights

The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that...
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the...
View all expert insights

Competitive Benchmarking Reports

Pharma Precision Medicine Readiness Report 2019
PM Readiness Report 2018 Summary
View all reports


FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with >5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved...
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of...
View all publications